Spotlight on Virtual ISPOR 2020 News
Spotlight on COVID-19
The COVID-19 pandemic was a topic touched on in many of the conference's sessions, including each of the plenary sessions. Additionally, a special, preconference plenary session was held on May 14 featuring keynote speaker Mark McClellan, MD, PhD, Director of the Duke-Margolis Center for Health Policy in Washington, DC, USA. This special session was made available free to all.
Health Economics and Outcomes Research in the Era of COVID-19 [An ISPOR News Report]
COVID-19—Calling All HEOR Stakeholders [The Evidence Base]
Spotlight on Health Policy
The first plenary session of the conference centered on the future of health policy with perspectives from both sides of the Atlantic.
Designing Health Policy for the Future [An ISPOR News Report]
Both Necessity and Science Give Rise to Invention [The Evidence Base]
Spotlight on Big Data and Real-World Evidence
Big data, artificial intelligence, and real-world data were the focus of a number of Virtual ISPOR 2020 sessions, including the second plenary, "HEOR and Clinical Decision Making—Advancing Meaningful Progress."
How Big Data and Artificial Intelligence Can Help Improve Healthcare Decision Making [An ISPOR News Report]
Moving From Population Health to 'Precision Population Health' [The Evidence Base]
Spotlight on HEOR Methodology
A number of Virtual ISPOR 2020 sessions centered on methodology-related topics. In fact, the third and final plenary session, “On the Road to Enhanced Cost-Effectiveness Analysis—New Directions, New Milestones."
Innovative Approaches to Cost-Effectiveness Analysis in Healthcare [An ISPOR News Report]
Leaving the QALY Behind... But Not Completely [The Evidence Base]
And other reporting on Virtual ISPOR 2020 sessions also included the following:
US Considering International Reference Pricing for Pharmaceutical Drugs [American Pharmacy News]
International Reference Pricing Gets Thumbs-Down From ISPOR Panel [The Center for Biosimilars]
Canada Grapples With Drug Price Escalation [The Center for Biosimilars]
Study Shows Variations in RWE Citation Frequency [The Center for Biosimilars]
ISPOR Panelists Weigh the Success of Alternative Payment Models [The Center for Biosimilars]
Panelists Advocate for Global Collaboration in Real-World Evidence Effort [The Center for Biosimilars]
Identifying and Addressing Multi-Stakeholder Gaps in Value Assessment [Journal of Clinical Pathways]
Virtual ISPOR 2020 Conference Coverage in Portuguese [Oncologia Brasil]
The reporting on Virtual ISPOR 2020 from external news sources reflects the views of the authors/media outlets and is not endorsed by ISPOR.